Dermatology

Filter

Dermatologist assessing plaque psoriasis while reviewing roflumilast for psoriasis meta analysis results

Roflumilast for Psoriasis Shows Early Benefit

February 2026

Roflumilast for psoriasis improved Global Assessment scores and was well tolerated versus placebo by Week 8 in a systematic review.

Dermatologist assessing plaque psoriasis while reviewing roflumilast for psoriasis meta analysis results

Roflumilast for Psoriasis Shows Early Benefit

Roflumilast for psoriasis improved Global Assessment scores and was well tolerated versus placebo by Week 8 in a systematic review.

Dermatology exam lamp in clinic for plaque psoriasis care after vunakizumab discontinuation

Vunakizumab Discontinuation Predicts Plaque Psoriasis Remission

After vunakizumab discontinuation, many plaque psoriasis patients maintained PASI 90, but BMI and interruptions predicted relapses.

Botanical extracts and toxic elements risk assessment concept with supplement capsules and laboratory testing

Botanical Extracts Add Little, Raise Toxic Elements

Botanical extracts provided negligible nutrition however could increase element exposure; inorganic arsenic and lead were concerns.

Medical trainee in scrubs smiling in a hospital corridor

Mini-Clinical Evaluation Exercise Improves Resident Self-Assessment

Mini-CEX self-assessment training plus feedback improved dermatology residents’ exam skills and rating alignment well in practice.

Perioperative liposomal bupivacaine injection prepared for dermatologic surgery postoperative pain control

Postoperative Analgesia in Dermatologic Surgery Shows Low Adverse Events

Perioperative liposomal bupivacaine injections showed minimal adverse events in 129 dermatologic surgery patients in a new review.

hidradenitis suppurativa patient-reported outcome measures questionnaire assessing quality of life and symptoms

Hidradenitis Suppurativa Patient-Reported Outcome Measures Reviewed

A review found seven hidradenitis suppurativa patient-reported key outcome measures, with HiSQOL-17 performing best across studies.

Optical coherence tomography imaging concept showing skin structure changes during risankizumab treatment for psoriasis

Risankizumab Shows Deep Skin Response in Psoriasis

Risankizumab delivered sustained psoriasis clearance and reduced subclinical inflammation on OCT imaging across 52 weeks follow-up.

Dermatologist assessing plaque psoriasis severity at a follow-up visit during apremilast treatment

Registry Data Show Apremilast Benefits in Psoriasis

Real-world PsoBest data show apremilast improved psoriasis severity, involvement, and quality of life over 12 months in usual care.

Loading posts...

1 2 3 … 22 Next »